Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#11 / 24 Total
RAL - Ralliant Corp - Stock Price Chart
TickerRAL [NYSE]
CompanyRalliant Corp
CountryUSA
IndustryElectronic Components
Market Cap5.12BEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume6.36M52W Range45.25 - 54.60
Jul-03-25Initiated BofA Securities Underperform $48
PMN - ProMIS Neurosciences Inc - Stock Price Chart
TickerPMN [NASD]
CompanyProMIS Neurosciences Inc
CountryCanada
IndustryBiotechnology
Market Cap14.13MEPS (ttm)-0.04
P/E-EPS this Y-684.85%
Forward P/E-EPS next Y14.51%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.49EPS Q/Q-13.27%
Dividend-Sales Q/Q-
Insider Own29.56%Inst Own24.09%
Insider Trans0.16%Inst Trans-12.90%
Short Float0.61%EarningsMay 12/b
Analyst Recom1.00Target Price5.67
Avg Volume46.23K52W Range0.45 - 2.37
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cashman NeilChief Scientific OfficerFeb 10 '25Buy0.9715,00014,59516,617Feb 12 05:21 PM
Shafmaster Madge K.DirectorSep 24 '24Buy1.3070,00091,028208,333Sep 24 06:56 PM
Shafmaster Madge K.DirectorSep 23 '24Buy1.2870,00089,656138,333Sep 24 06:56 PM
Shafmaster Madge K.DirectorSep 20 '24Buy1.2560,00075,06668,333Sep 24 06:56 PM
GORDON MICHAEL S10% OwnerSep 16 '24Buy1.2276,93194,07176,931Sep 18 04:15 PM
TELO - Telomir Pharmaceuticals Inc - Stock Price Chart
TickerTELO [NASD]
CompanyTelomir Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap34.23MEPS (ttm)-0.42
P/E-EPS this Y44.64%
Forward P/E-EPS next Y9.68%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q67.50%
Dividend-Sales Q/Q-
Insider Own42.03%Inst Own12.39%
Insider Trans0.00%Inst Trans3.31%
Short Float12.12%EarningsMay 28
Analyst Recom1.00Target Price15.50
Avg Volume252.85K52W Range1.18 - 8.40
Jun-18-25 09:15AM Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging (ACCESSWIRE) -5.38%
09:00AM EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria (Benzinga)
Jun-13-25 01:58PM TELO Rises on Promising Telomir-1 Preclinical Results (Insider Monkey)
Jun-11-25 09:30AM Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model (ACCESSWIRE)
Jun-05-25 08:30AM Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome (ACCESSWIRE)
07:41AM EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder (Benzinga)
Jun-02-25 08:30AM Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform (ACCESSWIRE) +7.97%
May-29-25 08:30AM Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints (ACCESSWIRE)
May-21-25 09:00AM Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND (ACCESSWIRE) -6.99%
08:15AM EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND (Benzinga)
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm's initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.
NEHC - New Era Helium Inc - Stock Price Chart
TickerNEHC [NASD]
CompanyNew Era Helium Inc
CountryUSA
IndustryOil & Gas E&P
Market Cap6.19MEPS (ttm)-1.30
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-914.89%
P/S12.14EPS next 5Y-
P/B-EPS Q/Q-873.58%
Dividend-Sales Q/Q-
Insider Own57.07%Inst Own2.14%
Insider Trans0.00%Inst Trans23.63%
Short Float37.17%Earnings-
Analyst Recom-Target Price-
Avg Volume5.33M52W Range0.43 - 12.29
Jul-01-25 08:45AM TCDC, New Era Helium's JV, signs LOI with Leading Global Provider of High Performance Cloud for AI and Modern Workloads for 250MW AI Data Center Joint Venture in the Permian Basin (Business Wire) -7.62%
Jun-26-25 09:30AM New Era Helium Strengthens Board with Strategic Appointments to Support AI Infrastructure Expansion (Business Wire)
Jun-19-25 11:23AM EnerCom Announces Liberty Energy and Baker Hughes as Keynote Speakers at the 30th Annual EnerCom Denver - The Energy Investment Conference (PR Newswire)
Jun-12-25 11:16AM New Era Helium Surges 125% on AI Data Center News (GuruFocus.com) +21.68%
07:00AM New Era Helium Advances Hyperscaler Discussions and Prepares for Board Expansion to Accelerate AI Infrastructure Strategy in the Permian Basin (Business Wire)
Jun-04-25 07:00AM New Era Helium Advances Permian Basin AI Data Center Strategy with Power MOU and Board Realignment to Support Data Center Vision (Business Wire)
May-21-25 02:43PM EnerCom Announces Premier Networking Events at the 30th Annual EnerCom Denver - The Energy Investment Conference, Including Charity Golf, Monday Cocktail Mixer, and Casino Night (PR Newswire)
Apr-30-25 08:30PM Correction: New Era Helium ROW Application Announcement (Business Wire) +7.49%
Apr-29-25 01:17PM EnerCom Opens Registration for the 30th Annual EnerCom Denver - The Energy Investment Conference (PR Newswire) -8.33%
07:30AM New Era Helium Receives Approval for Approximately 120 Miles of Rights-of-Way to Support Midstream Business Unit and Responsibly Sourced Gas Initiatives within the Pecos Slope, Permian Basin (Business Wire)
New Era Helium, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.
JXG - JX Luxventure Group Inc - Stock Price Chart
TickerJXG [NASD]
CompanyJX Luxventure Group Inc
CountryChina
IndustryApparel Manufacturing
Market Cap6.55MEPS (ttm)2.14
P/E0.76EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.13EPS next 5Y-
P/B0.07EPS Q/Q-57.68%
Dividend-Sales Q/Q-36.53%
Insider Own6.04%Inst Own0.14%
Insider Trans0.00%Inst Trans-83.53%
Short Float0.34%Earnings-
Analyst Recom-Target Price-
Avg Volume133.50K52W Range1.41 - 8.40
JX Luxventure Group, Inc. engages in the design, manufacture, distribution, and sale of casual menswear. It operates through the following segments: Tourism Products, Technology, and Cross-Board Merchandise. The The company was founded by Anna Polemis on January 26, 2012, and is headquartered in Haikou, China.
FOXO - FOXO Technologies Inc - Stock Price Chart
TickerFOXO [AMEX]
CompanyFOXO Technologies Inc
CountryUSA
IndustryHealth Information Services
Market Cap3.53MEPS (ttm)-7.93
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-7.61%
P/S0.49EPS next 5Y-
P/B0.06EPS Q/Q84.81%
Dividend-Sales Q/Q39918.93%
Insider Own2.27%Inst Own0.24%
Insider Trans0.00%Inst Trans0.27%
Short Float1.98%Earnings-
Analyst Recom-Target Price-
Avg Volume6.25M52W Range0.17 - 13.00
FOXO Technologies, Inc. develops genetic sequencing technology, artificial intelligence and bioinformatics tools. It operates through the FOXO Labs and FOXO Life segments. The FOXO Labs segment is involved in research and development and is commercializing proprietary epigenetic biomarker technology. The FOXO Life segment is involved in combining life insurance with a dynamic molecular health and wellness platform. The company was founded on April 27, 2020 and is headquartered in West Palm Beach, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kr8 ai Inc.10% OwnerJul 22 '24Sale0.251,300,000325,0000Jul 24 04:00 PM
WHITE MARK BRIANInterim CEOJul 22 '24Sale0.251,300,000325,0000Jul 24 04:00 PM
WARD MARTIN CHRISTOPHERInterim CFOJul 22 '24Sale0.251,300,000325,0000Jul 24 04:00 PM
CNC - Centene Corp - Stock Price Chart
TickerCNC [NYSE, S&P 500]
CompanyCentene Corp
CountryUSA
IndustryHealthcare Plans
Market Cap16.58BEPS (ttm)6.72
P/E4.96EPS this Y1.95%
Forward P/E4.17EPS next Y9.38%
PEG0.57EPS past 5Y14.96%
P/S0.10EPS next 5Y8.64%
P/B0.59EPS Q/Q21.75%
Dividend3.00%Sales Q/Q15.38%
Insider Own1.17%Inst Own98.49%
Insider Trans0.00%Inst Trans0.93%
Short Float1.89%EarningsJul 25/b
Analyst Recom2.23Target Price65.88
Avg Volume6.65M52W Range33.76 - 80.59
Jul-02-25Downgrade UBS Buy → Neutral $45
Jul-02-25Downgrade JP Morgan Overweight → Neutral $48
Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options' vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FASOLA KENNETH JOfficerMar 21 '25Proposed Sale59.068,500501,970Mar 21 10:37 AM
Greco ThomasDirectorDec 18 '24Buy59.7517,0001,015,75019,309Dec 19 05:39 PM
Dallas H JamesDirectorDec 16 '24Buy59.011,69399,9041,693Dec 17 07:34 PM
BLUME JESSICA L.DirectorDec 16 '24Buy59.4825014,870250Dec 17 07:33 PM
COUGHLIN CHRISTOPHER JDirectorDec 16 '24Buy59.4410,000594,40036,358Dec 17 07:33 PM
HLP - Hongli Group Inc - Stock Price Chart
TickerHLP [NASD]
CompanyHongli Group Inc
CountryChina
IndustrySteel
Market Cap56.17MEPS (ttm)-0.15
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S3.98EPS next 5Y-
P/B1.05EPS Q/Q-94.64%
Dividend-Sales Q/Q0.85%
Insider Own35.39%Inst Own0.00%
Insider Trans0.00%Inst Trans-77.42%
Short Float0.08%Earnings-
Analyst Recom-Target Price-
Avg Volume184.64K52W Range0.72 - 2.12
Hongli Group, Inc. is a holding company, which engages in conducting its businesses through its subsidiaries. Its business operation focuses on the design, production, deep processing, and sales of custom-made profile for machinery and equipment. The company was founded on February 9, 2021 and is headquartered in Weifang, China.
MTVA - MetaVia Inc - Stock Price Chart
TickerMTVA [NASD]
CompanyMetaVia Inc
CountryUSA
IndustryBiotechnology
Market Cap12.69MEPS (ttm)-3.36
P/E-EPS this Y68.96%
Forward P/E-EPS next Y0.23%
PEG-EPS past 5Y67.49%
P/S-EPS next 5Y26.17%
P/B1.28EPS Q/Q72.89%
Dividend-Sales Q/Q-
Insider Own64.31%Inst Own3.64%
Insider Trans58.76%Inst Trans3.46%
Short Float2.45%EarningsMay 14/a
Analyst Recom1.00Target Price13.75
Avg Volume716.09K52W Range0.63 - 5.16
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Woodworth Marshall HChief Financial OfficerJun 04 '25Buy0.7014,2009,94044,279Jun 04 04:01 PM
DONG-A ST CO., LTD10% OwnerMay 08 '25Buy0.714,647,8873,300,0009,995,679May 20 04:16 PM
ELV - Elevance Health Inc - Stock Price Chart
TickerELV [NYSE, S&P 500]
CompanyElevance Health Inc
CountryUSA
IndustryHealthcare Plans
Market Cap78.59BEPS (ttm)25.63
P/E13.57EPS this Y4.36%
Forward P/E8.88EPS next Y13.62%
PEG1.28EPS past 5Y6.81%
P/S0.43EPS next 5Y10.60%
P/B1.85EPS Q/Q0.19%
Dividend1.95%Sales Q/Q14.83%
Insider Own0.17%Inst Own92.63%
Insider Trans-2.17%Inst Trans-1.76%
Short Float1.11%EarningsJul 17/b
Analyst Recom1.70Target Price491.39
Avg Volume1.85M52W Range349.61 - 567.26
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye MarkEVP & CFOApr 24 '25Sale424.824,5881,949,07418,977Apr 25 04:17 PM
Kaye MarkOfficerApr 24 '25Proposed Sale424.814,5881,949,051Apr 24 05:10 PM
Penczek Ronald WCAO & ControllerMar 10 '25Sale415.13443183,9031,847Mar 11 04:20 PM
Penczek Ronald WOfficerMar 10 '25Proposed Sale415.13443183,904Mar 10 02:55 PM
Kendrick Charles Morgan JREVP & President, CommercialMar 05 '25Sale396.303,5041,388,63510,116Mar 05 05:52 PM
123